AU2020299974A1 - Prostate specific membrane antigen (PSMA) ligands and uses thereof - Google Patents
Prostate specific membrane antigen (PSMA) ligands and uses thereof Download PDFInfo
- Publication number
- AU2020299974A1 AU2020299974A1 AU2020299974A AU2020299974A AU2020299974A1 AU 2020299974 A1 AU2020299974 A1 AU 2020299974A1 AU 2020299974 A AU2020299974 A AU 2020299974A AU 2020299974 A AU2020299974 A AU 2020299974A AU 2020299974 A1 AU2020299974 A1 AU 2020299974A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- psma
- group
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/38—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a carbon atom of an acyclic unsaturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2024200850A AU2024200850B2 (en) | 2019-07-02 | 2024-02-09 | Prostate specific membrane antigen (psma) ligands and uses thereof |
| AU2025271182A AU2025271182A1 (en) | 2019-07-02 | 2025-11-24 | Prostate specific membrane antigen (PSMA) ligands and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19184015.6 | 2019-07-02 | ||
| EP19184015 | 2019-07-02 | ||
| PCT/EP2020/068386 WO2021001360A1 (en) | 2019-07-02 | 2020-06-30 | Prostate specific membrane antigen (psma) ligands and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024200850A Division AU2024200850B2 (en) | 2019-07-02 | 2024-02-09 | Prostate specific membrane antigen (psma) ligands and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020299974A1 true AU2020299974A1 (en) | 2022-01-27 |
Family
ID=67145647
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020299974A Abandoned AU2020299974A1 (en) | 2019-07-02 | 2020-06-30 | Prostate specific membrane antigen (PSMA) ligands and uses thereof |
| AU2024200850A Active AU2024200850B2 (en) | 2019-07-02 | 2024-02-09 | Prostate specific membrane antigen (psma) ligands and uses thereof |
| AU2025271182A Pending AU2025271182A1 (en) | 2019-07-02 | 2025-11-24 | Prostate specific membrane antigen (PSMA) ligands and uses thereof |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2024200850A Active AU2024200850B2 (en) | 2019-07-02 | 2024-02-09 | Prostate specific membrane antigen (psma) ligands and uses thereof |
| AU2025271182A Pending AU2025271182A1 (en) | 2019-07-02 | 2025-11-24 | Prostate specific membrane antigen (PSMA) ligands and uses thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230226227A1 (https=) |
| EP (1) | EP3993837A1 (https=) |
| JP (2) | JP7805170B2 (https=) |
| KR (1) | KR20220044496A (https=) |
| CN (3) | CN120441497A (https=) |
| AR (1) | AR119331A1 (https=) |
| AU (3) | AU2020299974A1 (https=) |
| BR (1) | BR112021026812A2 (https=) |
| CA (1) | CA3144557A1 (https=) |
| CL (1) | CL2021003525A1 (https=) |
| CO (1) | CO2021017708A2 (https=) |
| IL (1) | IL289039B1 (https=) |
| MX (1) | MX2022000136A (https=) |
| PH (1) | PH12021553284A1 (https=) |
| TW (1) | TW202114742A (https=) |
| WO (1) | WO2021001360A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230330278A1 (en) * | 2020-04-29 | 2023-10-19 | Novartis Ag | Methods for radiolabelling psma binding ligands and their kits |
| KR20260040237A (ko) | 2023-07-21 | 2026-03-24 | 노파르티스 아게 | Psma 표적 방사성 리간드 치료 요법 |
| WO2025125469A1 (en) | 2023-12-13 | 2025-06-19 | Swiss Rockets Ag | Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271026A1 (en) | 2000-07-11 | 2002-01-21 | Bml, Inc. | Remedies for bone diseases |
| WO2013022797A1 (en) * | 2011-08-05 | 2013-02-14 | Molecular Insight Pharmaceuticals | Radiolabeled prostate specific membrane antigen inhibitors |
| LT4095130T (lt) * | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| HRP20240215T1 (hr) * | 2016-03-22 | 2024-04-26 | The Johns Hopkins University | Sredstva sa visokim afinitetom za ciljani učinak na membranski antigen specifičan za prostatu za endoradioterapiju raka prostate |
| WO2018222778A1 (en) * | 2017-05-30 | 2018-12-06 | The Johns Hopkins University | Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer |
| KR20250126870A (ko) * | 2018-02-06 | 2025-08-25 | 더 존스 홉킨스 유니버시티 | 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트 |
| WO2020028323A1 (en) * | 2018-07-30 | 2020-02-06 | The Johns Hopkins Universtiy | Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
-
2020
- 2020-06-30 CN CN202510573851.3A patent/CN120441497A/zh active Pending
- 2020-06-30 CN CN202510573926.8A patent/CN120441498A/zh active Pending
- 2020-06-30 WO PCT/EP2020/068386 patent/WO2021001360A1/en not_active Ceased
- 2020-06-30 PH PH1/2021/553284A patent/PH12021553284A1/en unknown
- 2020-06-30 MX MX2022000136A patent/MX2022000136A/es unknown
- 2020-06-30 US US17/622,060 patent/US20230226227A1/en active Pending
- 2020-06-30 CA CA3144557A patent/CA3144557A1/en active Pending
- 2020-06-30 CN CN202080047295.1A patent/CN114341118A/zh active Pending
- 2020-06-30 EP EP20734426.8A patent/EP3993837A1/en active Pending
- 2020-06-30 AU AU2020299974A patent/AU2020299974A1/en not_active Abandoned
- 2020-06-30 JP JP2021578240A patent/JP7805170B2/ja active Active
- 2020-06-30 BR BR112021026812A patent/BR112021026812A2/pt unknown
- 2020-06-30 KR KR1020227003148A patent/KR20220044496A/ko active Pending
- 2020-07-01 AR ARP200101868A patent/AR119331A1/es unknown
- 2020-07-02 TW TW109122386A patent/TW202114742A/zh unknown
-
2021
- 2021-12-15 IL IL289039A patent/IL289039B1/en unknown
- 2021-12-23 CO CONC2021/0017708A patent/CO2021017708A2/es unknown
- 2021-12-28 CL CL2021003525A patent/CL2021003525A1/es unknown
-
2024
- 2024-02-09 AU AU2024200850A patent/AU2024200850B2/en active Active
-
2025
- 2025-07-17 JP JP2025120662A patent/JP2025165975A/ja active Pending
- 2025-11-24 AU AU2025271182A patent/AU2025271182A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230226227A1 (en) | 2023-07-20 |
| AU2024200850B2 (en) | 2025-09-04 |
| CN120441497A (zh) | 2025-08-08 |
| TW202114742A (zh) | 2021-04-16 |
| JP7805170B2 (ja) | 2026-01-23 |
| PH12021553284A1 (en) | 2022-08-01 |
| AU2024200850A1 (en) | 2024-02-29 |
| JP2022538478A (ja) | 2022-09-02 |
| BR112021026812A2 (pt) | 2022-02-22 |
| JP2025165975A (ja) | 2025-11-05 |
| CN120441498A (zh) | 2025-08-08 |
| IL289039B1 (en) | 2026-03-01 |
| AU2025271182A1 (en) | 2025-12-18 |
| IL289039A (en) | 2022-02-01 |
| CL2021003525A1 (es) | 2022-10-21 |
| CA3144557A1 (en) | 2021-01-07 |
| CN114341118A (zh) | 2022-04-12 |
| KR20220044496A (ko) | 2022-04-08 |
| MX2022000136A (es) | 2022-04-27 |
| EP3993837A1 (en) | 2022-05-11 |
| AR119331A1 (es) | 2021-12-09 |
| CO2021017708A2 (es) | 2022-05-20 |
| WO2021001360A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111285918B (zh) | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 | |
| ligan et al. | 99mTc-ethylenedicysteine-folate: a new tumor imaging agent. Synthesis, labeling and evaluation in animals | |
| AU2025271182A1 (en) | Prostate specific membrane antigen (PSMA) ligands and uses thereof | |
| JP2016535013A (ja) | 前立腺特異的膜抗原（ｐｓｍａ）の標識インヒビター、前立腺癌の治療のための画像化剤および薬剤としてのその使用 | |
| EP4474379A1 (en) | Peptide urea derivative, pharmaceutical composition containing peptide urea derivative, and application of peptide urea derivative | |
| JP2022513630A (ja) | 治療および画像化のためのデンドリマー | |
| Moon et al. | Development of a Ga-68 labeled PET tracer with short linker for prostate-specific membrane antigen (PSMA) targeting | |
| WO2023030509A1 (zh) | 一种肽脲素衍生物、含其的药物组合物及其应用 | |
| Huang et al. | Advancing cancer therapy with a heptamethine carbocyanine dye-conjugated radionuclide drug | |
| Yu et al. | Evaluation of 111In-DOTA-F56 peptide targeting VEGFR1 for potential non-invasive gastric cancer xenografted tumor mice Micro-SPECT imaging | |
| CN116782956A (zh) | 用作诊疗剂的放射性标记的α-Vβ-3和/或α-Vβ-5整合素拮抗剂 | |
| US20260007781A1 (en) | Prostate specific membrane antigen (psma) ligands and uses thereof | |
| CN119874628B (zh) | 一种含氮化合物及其制备方法与用途 | |
| CN105884646B (zh) | 一种锝‑99m标记的美法仑配合物及其制备方法与用途 | |
| KR20210102874A (ko) | 방사성 표지된 gprp 길항제 및 계면활성제를 포함하는 약학적 조성물 | |
| Ertay et al. | 99m Tc-exorphin C: A new peptide radiopharmaceutical for tumor imaging | |
| CN120349373A (zh) | 一种含氮化合物及其制备方法与用途 | |
| US20150112043A1 (en) | Small peptide specific for lung cancer and application thereof | |
| CN119112891A (zh) | 基于联合给药策略的靶向parp诊疗一体化试剂 | |
| KR20240115844A (ko) | 암의 치료용 화합물 및 이의 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |